The Pediatric Infectious Disease Journal. 26(1):1-7, JANUARY 2007

DOI: 10.1097/01.inf.0000247070.60063.09

,  

PMID: 17195697

Issn Print: 0891-3668

Publication Date: January 2007


Share this on facebook   Share this on Twitter   Share this on LinkedIn   Email this article  



Print

Immunogenicity and Reactogenicity of Primary Immunization With a Novel Combined Haemophilus influenzae Type b and Neisseria meningitidis Serogroup C-Tetanus Toxoid Conjugate Vaccine Coadministered With a Diphtheria–Tetanus–Acellular Pertussis–Hepatitis B–Inactivated Poliovirus Vaccine at 2, 4 and 6 Months

Juan Tejedor;Manuel Moro;Jesús Ruiz-Contreras;Javier Castro;José Gómez-Campderá;María Navarro;José Merino;Ana Martín-Ancel;Joan Roca;Manuel García-del-Rí;Antonio Jurado;Francisco Díez-Delgado;Félix Omeñaca;José García-Sicilia;Reyes Boceta;Pilar García-Corbeira;Alix Collard;Dominique Boutriau;Lode Schuerman;Jeanne-Marie Jacquet;

+ Author Information


    loading  Checking for direct PDF access through Ovid

Abstract

Background:This phase II study evaluated the immunogenicity and reactogenicity of primary vaccination with a novel Hib-MenC conjugate vaccine (GlaxoSmithKline [GSK] Biologicals) coadministered with DTPa-HBV-IPV (GSK Biologicals) at 2, 4 and 6 months.Methods:Healthy infants were randomized to receive Hib-MenC coadministered with DTPa-HBV-IPV (N = 117) or MenC-CRM (Wyeth) coadministered with DTPa-HBV-IPV/Hib (GSK Biologicals; N = 120) at 2, 4 and 6 months. Antibody concentrations were measured before vaccination and after doses 2 and 3. Solicited local and general symptoms, unsolicited symptoms and serious adverse events (SAEs) were recorded.Results:All subjects in the Hib-MenC group had seroprotective titers of anti-PRP antibodies (≥0.15 μg/mL) and SBA-MenC titers (≥1:8) 1 month after the third dose. These responses were noninferior to those seen in the control group, in which a 99.1% seroprotection rate was observed for both Hib and MenC. At that time, anti-PRP and SBA-MenC GMTs were significantly higher in the Hib-MenC group (12.8 μg/mL and 2467.1 μg/mL, respectively) than in the control group (3.8 μg/mL and 1833.7 μg/mL). High seroprotection rates were already observed after the second dose of Hib-MenC; 96.4% and 100% of subjects were seroprotected to Hib and MenC, respectively. Immune responses to coadministered antigens were unimpaired; seroprotection/vaccine response rates ≥96.5% were recorded postdose 3 in the Hib-MenC group. No differences in reactogenicity were seen between the 2 study groups.Conclusions:Coadministration of a Hib-MenC conjugate vaccine with DTPa-HBV-IPV is well tolerated and immunogenic, and does not impair the immune response to any of the coadministered antigens.

Related Topics

    Related Articles

        loading  Loading Related Articles